- Home
- PEBK vs NBP Comparison
PEBK vs NBP Comparison
Compare PEBK & NBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PEBK | NBP |
|---|---|---|
| Founded | 1912 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 230.2M | 205.9M |
| IPO Year | 2012 | 2019 |
Fundamental Metrics
Financial Performance| Metric | PEBK | NBP |
|---|---|---|
| Price | $44.15 | $1.64 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | 20.0K | ★ 241.0K |
| Earning Date | 04-20-2026 | 04-07-2026 |
| Dividend Yield | ★ 2.58% | N/A |
| EPS Growth | ★ 21.48 | N/A |
| EPS | ★ 1.76 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $24.98 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $27.33 | $1.46 |
| 52 Week High | $45.78 | $5.19 |
Technical Indicators
Market Signals| Indicator | PEBK | NBP |
|---|---|---|
| Relative Strength Index (RSI) | 53.10 | 40.82 |
| Support Level | $41.53 | N/A |
| Resistance Level | $45.46 | $1.67 |
| Average True Range (ATR) | 0.95 | 0.07 |
| MACD | 0.02 | -0.02 |
| Stochastic Oscillator | 58.88 | 21.67 |
Price Performance
Historical ComparisonAbout PEBK Peoples Bancorp of North Carolina Inc.
Peoples Bancorp of North Carolina Inc is a bank holding company. It is a state-chartered commercial bank serving Lincolnton, Newton, Denver, Catawba, Conover, Maiden, Claremont, Hiddenite, Hickory, Charlotte, Cornelius, Raleigh and Cary, North Carolina. It has a diversified loan portfolio with no foreign loans and few agricultural loans. The company's main source of income is dividends declared and paid by the Bank on its capital stock.
About NBP NovaBridge Biosciences American Depositary Shares
NovaBridge Biosciences operates as a biotechnology platform, combining business development and clinical research to identify and advance pharmaceutical assets. Its inventive immuno-oncology pipeline consists of three clinical stage programs, givastomig; uliledlimab; and ragistomig. Its core product, givastomig, is a potential in-class CLDN18.2 bispecific antibody for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies.